 | • レポートコード：MRC2301B058 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、230ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥692,860 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,392,860 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社発行の当調査レポートでは、2021年に3,017.14百万ドルであった世界のナルコレプシー治療市場規模が、2022年に3,414.62百万ドルに達し、2027年には6,399.60百万ドルまで年平均13.35%で成長すると予測しています。当レポートは、ナルコレプシー治療の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬物クラス別（中枢神経系刺激薬、充血除去剤、セロトニン再取り込み阻害剤、血管拡張薬）分析、ナルコレプシー種類別（ナルコレプシー1型、ナルコレプシー2型）分析、エンドユーザー別（ドラッグストア、電子商取引、小売薬局）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でまとめております。なお、当書には、Addrenex Pharmaceuticals, Inc.、Arena Pharmaceuticals, Inc.、Avadel Pharmaceuticals plc、Axsome Therapeutics、BIOPROJET、GlaxoSmithKline PLC、Graymark Healthcare Inc.、Harmony Biosciences LLC、Jazz Pharmaceuticals plc、Johnson＆Johnson Services Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のナルコレプシー治療市場規模：薬物クラス別 - 中枢神経系刺激薬の市場規模 - 充血除去剤の市場規模 - セロトニン再取り込み阻害剤の市場規模 - 血管拡張薬の市場規模 ・世界のナルコレプシー治療市場規模：ナルコレプシー種類別 - ナルコレプシー1型の市場規模 - ナルコレプシー2型の市場規模 ・世界のナルコレプシー治療市場規模：エンドユーザー別 - ドラッグストアにおける市場規模 - 電子商取引における市場規模 - 小売薬局における市場規模 ・世界のナルコレプシー治療市場規模：地域別 - 南北アメリカのナルコレプシー治療市場規模 アメリカのナルコレプシー治療市場規模 カナダのナルコレプシー治療市場規模 ブラジルのナルコレプシー治療市場規模 ... - アジア太平洋のナルコレプシー治療市場規模 日本のナルコレプシー治療市場規模 中国のナルコレプシー治療市場規模 インドのナルコレプシー治療市場規模 韓国のナルコレプシー治療市場規模 台湾のナルコレプシー治療市場規模 ... - ヨーロッパ/中東/アフリカのナルコレプシー治療市場規模 イギリスのナルコレプシー治療市場規模 ドイツのナルコレプシー治療市場規模 インドのナルコレプシー治療市場規模 フランスのナルコレプシー治療市場規模 ロシアのナルコレプシー治療市場規模 ... - その他地域のナルコレプシー治療市場規模 ・競争状況 ・企業情報 |
The Global Narcolepsy Treatment Market size was estimated at USD 3,017.14 million in 2021 and expected to reach USD 3,414.62 million in 2022, and is projected to grow at a CAGR 13.35% to reach USD 6,399.60 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Narcolepsy Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Class, the market was studied across CNS Stimulants, Decongestants, Serotonin Reuptake Inhibitors, and Vasopressors.
Based on Narcolepsy Type, the market was studied across Narcolepsy Type 1 and Narcolepsy Type 2.
Based on End User, the market was studied across Drug Stores, E-commerce, and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Narcolepsy Treatment market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Narcolepsy Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Narcolepsy Treatment Market, including Addrenex Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., Avadel Pharmaceuticals plc, Axsome Therapeutics, BIOPROJET, GlaxoSmithKline PLC, Graymark Healthcare Inc., Harmony Biosciences LLC, Jazz Pharmaceuticals plc, Johnson & Johnson Services Inc., Ligand Pharmaceuticals, Midas Pharma GmbH, Novartis AG, Pfizer Inc., Shire Plc, and Teva Pharmaceutical Industries Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Narcolepsy Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Narcolepsy Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Narcolepsy Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Narcolepsy Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Narcolepsy Treatment Market?
6. What is the market share of the leading vendors in the Global Narcolepsy Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Narcolepsy Treatment Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising number of chronic neurological disorder
5.1.1.2. Increasing cases of sleep disorder narcolepsy
5.1.1.3. Growing consumer awareness regarding narcolepsy treatment
5.1.2. Restraints
5.1.2.1. Adverse effects of the narcolepsy treatment
5.1.3. Opportunities
5.1.3.1. Rise in the research activities related to the narcolepsy treatment
5.1.3.2. Growing number of product launches and favorable reimbursement policies
5.1.4. Challenges
5.1.4.1. Costly diagnosis and treatment of narcolepsy
5.2. Cumulative Impact of COVID-19
6. Narcolepsy Treatment Market, by Drug Class
6.1. Introduction
6.2. CNS Stimulants
6.3. Decongestants
6.4. Serotonin Reuptake Inhibitors
6.5. Vasopressors
7. Narcolepsy Treatment Market, by Narcolepsy Type
7.1. Introduction
7.2. Narcolepsy Type 1
7.3. Narcolepsy Type 2
8. Narcolepsy Treatment Market, by End User
8.1. Introduction
8.2. Drug Stores
8.3. E-commerce
8.4. Retail Pharmacies
9. Americas Narcolepsy Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Narcolepsy Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Narcolepsy Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Addrenex Pharmaceuticals, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Arena Pharmaceuticals, Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Avadel Pharmaceuticals plc
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Axsome Therapeutics
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. BIOPROJET
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. GlaxoSmithKline PLC
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Graymark Healthcare Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Harmony Biosciences LLC
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Jazz Pharmaceuticals plc
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Johnson & Johnson Services Inc.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Ligand Pharmaceuticals
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Midas Pharma GmbH
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Novartis AG
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Pfizer Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Shire Plc
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Teva Pharmaceutical Industries Ltd.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing